BiomOrgan Limited is pleased to share that, out of 200+ participating teams, BiomOrgan and PDOHub™ have been shortlisted into the Top 10 finalists at the EQT Impact Challenge 2026.

Today, Benson To, COO of BiomOrgan Limited & Co‑Founder of PDOHub™ HK, and Dr. Linda Huang, CSO of BiomOrgan Limited & Co‑Founder of PDOHub™ HK, presented our integrated organoid‑based precision medicine platform. The presentation highlighted how organoid technologies are reshaping oncology and translational research across Asia.

Being recognized among the Top 10 is a meaningful milestone for our team. It reflects the strength of our scientific foundation built at HKU and CVVT, and underscores the growing importance of human‑relevant organoid models in accelerating clinical decision, drug screening, and early therapeutic discovery.

We extend our appreciation to EQT Group, SCMP Live, our collaborators, and the broader scientific and clinical community for their continued support. We are committed to advancing organoid‑driven innovation and delivering impactful solutions for healthcare partners across the region.

? BiomOrgan — Innovating Human‑Relevant Models for Tomorrow’s Medicine.